2025-03-27T11:01:25-05:00 2024-06-30 410746749 CLIFTONLARSONALLEN LLP 4 BATTERYMARCH PARK SUITE 100 QUINCY MA 02169 990 2023-07-01 851085804 PHARE BIO INC PHAR 6174265900 303 CONGRESS STREET 2ND FLOOR BOSTON MA 02210 AKHILA KOSARAJU CEO AND PRESIDENT 6174265900 2025-03-20 1 0 DANIELLE NIHILL P01350943 7819821001 2025-03-20 2023 2025-03-06 01:10:19Z AKHILA KOSARAJU 303 CONGRESS STREET 2ND FLOOR BOSTON MA 02210 2148132 0 X WWW.PHAREBIO.ORG X 2020 MA PHARE BIO USES AI/DEEP LEARNING TO DEVELOP NOVEL ANTIBIOTICS TO TACKLE ANTIMICROBIAL RESISTANCE. 7 6 3 7 0 0 2007643 2134302 0 0 26 13335 1844 495 2009513 2148132 13192 0 0 0 883402 975699 0 0 4511 352916 485304 1249510 1461003 760003 687129 1837494 2586256 88135 76903 1749359 2509353 X PHARE BIO'S MISSION IS TO DEVELOP CRITICALLY NEEDED ANTIBIOTICS TO ADDRESS A LOOMING CRISIS IN ANTIBIOTIC RESISTANCE. USING NOVEL AI AND DEEP LEARNING APPROACHES, PHARE BIO AIMS TO RAPIDLY DISCOVER AND DEVELOP NEW CLASSES OF ANTIBIOTICS AGAINST THE DEADLIEST PATHOGENS, AND ENSURE THAT THESE THERAPIES REACH THE PATIENTS IN GREATEST NEED. 0 0 1097096 0 495 PHARE BIO'S PROGRAM MANDATE IS TO DEVELOP CRITICALLY NEEDED ANTIBIOTICS TO ADDRESS A LOOMING CRISIS IN ANTIBIOTIC RESISTANCE. PHARE BIO HAS A NUMBER OF PROMISING EARLY-STAGE PIPELINE PROJECTS AND IS CONDUCTING EXTENSIVE IN VITRO AND IN VIVO DRUG DEVELOPMENT STUDIES TO ADVANCE POTENTIAL ANTIBIOTICS THROUGH THE RESEARCH AND DEVELOPMENT PROCESS. THESE ANTIBIOTIC CANDIDATES ARE DISCOVERED VIA A NOVEL AI/DEEP LEARNING PLATFORM DEVELOPED BY PROFESSOR JIM COLLINS' LAB AT MIT (PHARE BIO'S AI DISCOVERY PARTNER AND CO-FOUNDER) AND OPTIMIZED FOR FUTURE CLINICAL APPLICATION AT PHARE BIO. WITH THIS CUTTING-EDGE PLATFORM AND A NONPROFIT BUSINESS MODEL, PHARE BIO IS DEVELOPING NEW CLASSES OF ANTIBIOTICS AND UNIQUELY ADDRESSING ECONOMIC CHALLENGES FACING THE ANTIBIOTIC MARKET. IN THIS PAST YEAR, PHARE BIO DISCOVERED AND STUDIED ADDITIONAL NOVEL ANTIBIOTICS WITH ITS GENERATIVE AI DRUG DESIGN PLATFORM, FURTHER ADVANCING ITS EARLY-STAGE PIPELINE. 1097096 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 12 0 1 3 1 0 0 0 0 0 0 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA NY X AKHILA KOSARAJU 6174265900 303 CONGRESS STREET BOSTON MA 02210 AKHILA KOSARAJU CEO & PRESIDENT 40.00 X X 549218 0 14184 WILLIAM FOSTER CHAIR & TREASURER 1.00 X X 0 0 0 STEVE ELLIS DIRECTOR 1.00 X 0 0 0 JAMES COLLINS DIRECTOR 1.00 X 0 0 0 JOSE-CARLOS GUTTIEREZ-RAMOS DIRECTOR 1.00 X 0 0 0 ROBERT PLENGE DIRECTOR 1.00 X 0 0 0 SUSAN URAHN DIRECTOR 1.00 X 0 0 0 CLAIRE NISHIOKA ROBINSON SENIOR DIRECTOR, BUSINESS STRATEGIES 40.00 X 159583 0 7634 708801 0 21818 2 0 1 0 0 2134302 2134302 13335 13335 MISCELLANEOUS INCOME 900003 495 495 495 2148132 495 0 13335 X 588532 500252 88280 328401 279141 49260 15648 13301 2347 43118 36650 6468 15037 7259 3267 4511 8813 8813 81604 81604 335573 251680 83893 6612 6612 9097 9097 5060 5060 13047 13047 2450 2450 4450 4450 TAXES 310 310 3251 3251 1461003 1097096 359396 4511 275000 208688 553421 3689 3800 1005384 2373768 1837494 2586256 88135 76903 88135 76903 X 1749359 2509353 1749359 2509353 1837494 2586256 X 687129 83837 -11717 745 X 0 1 X 1 0 X 1057242 1557143 2007643 2134302 6756330 1057242 1557143 2007643 2134302 6756330 3619059 3137271 26 13335 13361 1680 1680 1844 495 2339 6773710 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISC INCOME - 2022 AMOUNT: $ 1,844. 2023 AMOUNT: $ 495. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 2232714 83837 745 84582 2148132 0 2148132 1461003 0 1461003 0 1461003 PART XI, LINE 2D - OTHER ADJUSTMENTS: FOREIGN CURRENCY GAIN/LOSS 745. X X X X X 0 0 0 0 0 0 0 0 0 AKHILA KOSARAJU CEO & PRESIDENT 417218 0 132000 0 0 0 0 0 14184 0 563402 0 0 0 CLAIRE NISHIOKA ROBINSON SENIOR DIRECTOR, BUSINESS STRATEGIES 114583 0 45000 0 0 0 0 0 7634 0 167217 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B PHARE BIO'S DIRECTORS, OFFICERS, ACCOUNTING AND LEGAL TEAMS WILL REVIEW THE 990 PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ALL OFFICERS AND DIRECTORS ARE TRAINED ANNUALLY ON THE PHARE BIO INC CONFLICT OF INTEREST POLICY (ADOPTED MAY 2020) AND MUST ACKNOWLEDGE ADHERENCE TO THE POLICY. ANY CONFLICT OF INTEREST DISCLOSURES ARE REQUIRED AND MUST BE UPDATED WITH ANY NEW POTENTIAL CONFLICTS. THE PRESIDENT AND BOARD OF DIRECTORS OVERSEE ALL CONFLICT OF INTEREST DISCLOSURES AND COMPLIANCE PER THE PHARE BIO INC CONFLICT OF INTEREST POLICY. SHOULD A POTENTIAL CONFLICT ARISE, THE BOARD WILL DETERMINE WHETHER A CONFLICT EXISTS AND VOTE ON ANY APPROPRIATE ACTIONS, BE IT DISCIPLINARY, CORRECTIVE OR OTHERWISE. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD, LED BY THE CEO AND REVIEWED BY THE TREASURER, DETERMINES ALL OFFICER COMPENSATION BY CONDUCTING AN INDUSTRY COMPARABLES ANALYSIS FOR BOTH SALARIES AND BONUSES. BONUSES ARE APPROVED BY THE BOARD AT THE ANNUAL BOARD MEETING (ALONG WITH THE ANNUAL BUDGET, WHICH INCLUDES THE SALARY AND COMPENSATION BUDGET) BASED ON ACHIEVEMENT OF PERFORMANCE METRICS SET BY THE ORGANIZATION AND APPROVED BY THE BOARD. THE PROCESS DESCRIBED HERE WAS LAST COMPLETED IN 2024. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS FINANCIAL STATEMENTS, POLICIES, AND OTHER DOCUMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G CONTRACT SERVICES: PROGRAM SERVICE EXPENSES 251,680. MANAGEMENT AND GENERAL EXPENSES 83,893. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 335,573. FORM 990, PART XI, LINE 9: FOREIGN CURRENCY GAIN/LOSS 745. PHARE DISCOVERIES LLC 303 CONGRESS ST BOSTON MA 02210 612087958 SCIENTIFIC RESEARCH MA 0 0 PHARE BIO INC